| abstract |
This disclosure relates to novel quinazoline compounds of formula (I) as defined in the specification and to compositions comprising the novel compounds. These compounds are useful anticancer agents in particular in inhibiting the function of EGF receptor tyrosine kinase, HER1 tyrosine kinase and HER2 tyrosine kinase. Accordingly, said disclosure also relates to methods of treating hyperproliferative diseases or conditions such as various cancers and benign prostatic hyperplasia (BPH) by using these novel compounds or compositions comprising the novel compounds. |